Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 7 | 2026 | 1723 | 2.000 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 154 | 1.690 |
Why?
|
| Genomics | 2 | 2025 | 293 | 0.950 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2025 | 47 | 0.890 |
Why?
|
| Complementary Therapies | 1 | 2025 | 51 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 220 | 0.800 |
Why?
|
| Radiotherapy | 1 | 2021 | 21 | 0.710 |
Why?
|
| Mastectomy | 1 | 2021 | 21 | 0.710 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 53 | 0.700 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 704 | 0.700 |
Why?
|
| Neoplasms | 5 | 2025 | 1377 | 0.690 |
Why?
|
| Weight Loss | 1 | 2021 | 137 | 0.660 |
Why?
|
| Weight Gain | 1 | 2021 | 139 | 0.650 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 92 | 0.450 |
Why?
|
| Aged | 8 | 2026 | 8214 | 0.440 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 183 | 0.430 |
Why?
|
| Middle Aged | 9 | 2026 | 12222 | 0.390 |
Why?
|
| Female | 12 | 2026 | 24698 | 0.380 |
Why?
|
| Adult | 9 | 2026 | 13872 | 0.350 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 2853 | 0.340 |
Why?
|
| Prognosis | 2 | 2025 | 861 | 0.330 |
Why?
|
| Hawaii | 3 | 2025 | 2011 | 0.320 |
Why?
|
| Humans | 15 | 2026 | 43102 | 0.300 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2544 | 0.290 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2026 | 13 | 0.240 |
Why?
|
| Carboplatin | 1 | 2025 | 20 | 0.230 |
Why?
|
| Child of Impaired Parents | 1 | 2025 | 20 | 0.230 |
Why?
|
| Child Behavior | 1 | 2025 | 81 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 23 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 27 | 0.190 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 5 | 0.180 |
Why?
|
| Parents | 1 | 2025 | 370 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 173 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2026 | 1759 | 0.170 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1067 | 0.140 |
Why?
|
| Mutation | 1 | 2022 | 1177 | 0.130 |
Why?
|
| Telemedicine | 1 | 2021 | 234 | 0.130 |
Why?
|
| Young Adult | 1 | 2025 | 5080 | 0.100 |
Why?
|
| Small Molecule Libraries | 2 | 2010 | 62 | 0.090 |
Why?
|
| Thiadiazines | 1 | 2010 | 1 | 0.090 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Male | 3 | 2025 | 23409 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 157 | 0.080 |
Why?
|
| NADPH Dehydrogenase | 1 | 2009 | 11 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 199 | 0.080 |
Why?
|
| United States | 3 | 2026 | 5205 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 95 | 0.070 |
Why?
|
| Actins | 1 | 2009 | 164 | 0.070 |
Why?
|
| p21-Activated Kinases | 1 | 2008 | 21 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 213 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 127 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2009 | 321 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 159 | 0.060 |
Why?
|
| Homeostasis | 1 | 2008 | 192 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2026 | 290 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2025 | 374 | 0.050 |
Why?
|
| Selection Bias | 1 | 2021 | 13 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 152 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2025 | 1604 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2025 | 1546 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 152 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2021 | 161 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 587 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 215 | 0.040 |
Why?
|
| Risk Factors | 1 | 2026 | 3994 | 0.030 |
Why?
|
| Child | 1 | 2025 | 3443 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 719 | 0.030 |
Why?
|
| Adolescent | 1 | 2025 | 6081 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3156 | 0.020 |
Why?
|
| Methionine | 1 | 2010 | 27 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 99 | 0.020 |
Why?
|
| Fetal Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Pyrenes | 1 | 2009 | 26 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 72 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 139 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 267 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 423 | 0.020 |
Why?
|
| Naphthols | 1 | 2008 | 10 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2008 | 28 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 219 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2008 | 168 | 0.020 |
Why?
|
| Mice | 2 | 2009 | 6644 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 333 | 0.020 |
Why?
|
| Disulfides | 1 | 2008 | 95 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 462 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2008 | 416 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2008 | 281 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1455 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2676 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1019 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 16992 | 0.010 |
Why?
|